Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts

RECOMMENDED

Asthma

Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

★ 1 Recommended by Dr Martin Frey, Faculty Member

Health Qual Life Outcomes

Meys R, Franssen FME, Van 't Hul AJ, Bakke PS, Caruso M, Dahlén B, Fowler SJ, Geiser T, Howarth PH, Horváth I, Krug N, Behndig AF, Singer F, Musial J, Shaw DE, Montuschi P, Zee AHM, Sterk PJ, Roberts G, Kermani NZ, Incalzi RA, Louis R, Andersson LI, Wagers SS, Dahlén SE, Chung KF, Adcock IM, Spruit MA, U-BIOPRED Study Group

doi: 10.1186/s12955-024-02321-3

AsthmaRespiratory Tract Infection

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register

Respir Med

Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C

doi: 10.1016/j.rmed.2025.108203

Asthma

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry

J Asthma Allergy

Le TT, Price DB, Erhard C, Cook B, Quinton A, Katial R, Christoff GC, Perez-de-Llano L, Altraja A, Bergeron C, Bourdin A, Koh MS, Lehtimäki L, Mahboub B, Papadopoulos NG, Pfeffer P, Rhee CK, Carter V, Martin N, Tran TN, EVEREST Study Working Group

doi: 10.2147/JAA.S468068

RECOMMENDED

AsthmaCOPD

Cardiovascular Events in Patients with Severe Asthma-A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Granda P, Villamañán E, Laorden D, Carpio C, Collada V, Domínguez-Ortega J, de Las Vecillas L, Romero-Ribate D, Chaparro-Díaz OF, Lázaro Miguel-Sin T, Alloca-Álvarez DJ, Correa-Borit JM, Losantos I, Mir-Ihara P, Narváez-Fernández EJ, Quirce S, Álvarez-Sala R

doi: 10.3390/jcm13154299

RECOMMENDED

Asthma

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir J

Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE

doi: 10.1183/13993003.00316-2024

Asthma

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

Allergy Asthma Immunol Res

Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH

doi: 10.4168/aair.2025.17.3.384

COPD

Development and Validation of a Quantitative Score for the Criteria Clinical Control in Stable COPD Proposed in the Spanish COPD Guidelines (GesEPOC): Results of the EPOCONSUL Audit

J Clin Med

Calle Rubio M, Cataluña JJS, Miravitlles M, Navarrete BA, López-Campos JL, Ferrer MEF, Rodríguez Hermosa JL

doi: 10.3390/jcm14030707

RECOMMENDED

Asthma

Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G

doi: 10.3390/jcm14062075

COMMENTED

Asthma

XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Chest

Pelaia G, Jackson DJ, Nair P, Emmanuel B, Tran TN, Menzies-Gow A, Watt M, Kayaniyil S, Boarino S, Nuevo J, Pardal M, Shavit A, Shih VH, Cohen D, Loureiro C, Padilla-Galo A

doi: 10.1016/j.chest.2025.04.011

Related content

Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry

Cardiovascular Events in Patients with Severe Asthma-A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

Development and Validation of a Quantitative Score for the Criteria Clinical Control in Stable COPD Proposed in the Spanish COPD Guidelines (GesEPOC): Results of the EPOCONSUL Audit

Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study

XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma